By VETTAPHARMA reporter – Derek Roche: Incyte presented full Phase III frontMIND results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showing that tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP significantly improved progression-free survival in patients with newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL).
The study demonstrated a 25% reduction in the risk of disease progression or death compared with R-CHOP alone (HR 0.75; 95% CI, 0.59–0.96; P=0.0194) after a median follow-up of 35.2 months. The trial also met its key secondary endpoint of event-free survival.
frontMIND is a global Phase III randomized, double-blind, placebo-controlled study evaluating tafasitamab plus lenalidomide in combination with R-CHOP as first-line treatment for patients with newly diagnosed high-intermediate and high-risk DLBCL and high-grade B-cell lymphoma (HGBL).
According to the ASCO presentation, the three-year progression-free survival rate reached 67.3% in patients receiving tafasitamab plus lenalidomide and R-CHOP compared with 60.7% in patients receiving R-CHOP alone. Among patients with centrally confirmed diagnoses, the regimen reduced the risk of progression or death by 32%.
The study enrolled 899 patients globally, including individuals with high-intermediate and high-risk disease based on International Prognostic Index criteria. DLBCL remains the most common subtype of non-Hodgkin lymphoma, while patients with high-risk disease continue to experience substantial relapse rates despite frontline treatment with R-CHOP.
Safety findings were reported to be consistent with the established profiles of tafasitamab, lenalidomide and R-CHOP, with no new safety signals identified. Investigators noted that the study represents one of the few large Phase III frontline DLBCL trials to demonstrate improved clinical outcomes compared with R-CHOP, which has remained the standard frontline regimen for more than two decades.
The findings expand the potential role of tafasitamab beyond its currently approved relapsed or refractory lymphoma settings and support planned regulatory submissions in frontline DLBCL. For Incyte, successful expansion into first-line treatment could substantially broaden the commercial opportunity for tafasitamab within the global lymphoma market.
Quick FAQs
1. What Is Tafasitamab?
Tafasitamab is a CD19-targeting monoclonal antibody marketed as Monjuvi/Minjuvi for certain B-cell malignancies.
2. What Were the Key ASCO frontMIND Results?
The regimen reduced the risk of disease progression or death by 25% compared with R-CHOP alone and improved progression-free survival.
3. What Is the frontMIND Study?
frontMIND is a global Phase III trial evaluating tafasitamab plus lenalidomide and R-CHOP as first-line therapy for newly diagnosed high-risk DLBCL and HGBL.
4. What Is Diffuse Large B-Cell Lymphoma?
DLBCL is the most common form of non-Hodgkin lymphoma and is an aggressive cancer arising from B lymphocytes.
5. What Was the Three-Year Progression-Free Survival Rate?
Three-year progression-free survival was 67.3% with the tafasitamab regimen versus 60.7% with R-CHOP alone.
6. Why Are the ASCO Results Important?
The data support potential frontline expansion of tafasitamab and represent one of the few Phase III DLBCL studies showing improved outcomes over R-CHOP.
